Use of FDA’s accelerated approval pathway could be increased by broadening the definition of “unmet medical need” and narrowing the scope of what constitutes “available therapy,” a multi-stakeholder panel said at the Conference on Clinical Cancer Research Nov. 14.
Determining that any cancer setting in which no curative treatment exists constitutes an unmet medical need, and limiting the definition...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?